Literature DB >> 8670046

A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.

M P Cosma1, L Panariello, L Quadro, N A Dathan, O Fattoruso, V Colantuoni.   

Abstract

We demonstrate that a Hirschsprung (HSCR) mutation in the tyrosine kinase domain of the RET proto-oncogene abolishes in cis the tyrosine-phosphorylation associated with the activating mutation in multiple endocrine neoplasia type 2A (MEN2A) in transiently transfected Cos cells. Yet the double mutant RET2AHS retains the ability to form stable dimers, thus dissociating the dimerization from the phosphorylation potential. Co-transfection experiments with single and double mutants carrying plasmids RET2A and RET2AHS in different ratios drastically reduced the phosphorylation levels of the RET2A protein, suggesting a dominant-negative effect of the HSCR mutation. Also, the phosphorylation associated with the multiple endocrine neoplasia type 2B (MEN2B) allele was affected in experiments with single and double mutants carrying plasmids co-transfected under the same conditions. Finally, analysis of the enzymic activity of MEN2A and MEN2B tumours confirmed the relative levels of tyrosine phosphorylation observed in Cos cells, indicating that this condition, in vivo, may account for the RET transforming potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670046      PMCID: PMC1217061          DOI: 10.1042/bj3140397

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence.

Authors:  M Takahashi; Y Buma; H Hiai
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

2.  Loss of function effect of RET mutations causing Hirschsprung disease.

Authors:  B Pasini; M G Borrello; A Greco; I Bongarzone; Y Luo; P Mondellini; L Alberti; C Miranda; E Arighi; R Bocciardi
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

3.  Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.

Authors:  M Takahashi; Y Buma; T Iwamoto; Y Inaguma; H Ikeda; H Hiai
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

Review 4.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

Authors:  S K Hanks; A M Quinn; T Hunter
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

7.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

Authors:  H Donis-Keller; S Dou; D Chi; K M Carlson; K Toshima; T C Lairmore; J R Howe; J F Moley; P Goodfellow; S A Wells
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  Characterization of the ret proto-oncogene products expressed in mouse L cells.

Authors:  M Takahashi; N Asai; T Iwashita; T Isomura; K Miyazaki; M Matsuyama
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

10.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.

Authors:  R M Hofstra; R M Landsvater; I Ceccherini; R P Stulp; T Stelwagen; Y Luo; B Pasini; J W Höppener; H K van Amstel; G Romeo
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

View more
  4 in total

1.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 2.  Genetic basis of Hirschsprung's disease.

Authors:  Paul K H Tam; Mercè Garcia-Barceló
Journal:  Pediatr Surg Int       Date:  2009-06-12       Impact factor: 1.827

3.  SRY interference of normal regulation of the RET gene suggests a potential role of the Y-chromosome gene in sexual dimorphism in Hirschsprung disease.

Authors:  Yunmin Li; Tatsuo Kido; Maria M Garcia-Barcelo; Paul K H Tam; Z Laura Tabatabai; Yun-Fai Chris Lau
Journal:  Hum Mol Genet       Date:  2014-09-28       Impact factor: 6.150

4.  Oncological implications of RET gene mutations in Hirschsprung's disease.

Authors:  R H Sijmons; R M Hofstra; F A Wijburg; T P Links; R P Zwierstra; A Vermey; D C Aronson; G Tan-Sindhunata; G J Brouwers-Smalbraak; S M Maas; C H Buys
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.